Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54


An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages.

Tambyah PA, Oon J, Asli R, Kristanto W, Hwa SH, Vang F, Karwal L, Fuchs J, Santangelo JD, Gordon GS, Thomson C, Rao R, Dean H, Das SC, Stinchcomb DT.

Vaccine. 2019 Jul 18;37(31):4344-4353. doi: 10.1016/j.vaccine.2019.06.023. Epub 2019 Jun 20.


Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against Leishmania donovani.

Duthie MS, Van Hoeven N, MacMillen Z, Picone A, Mohamath R, Erasmus J, Hsu FC, Stinchcomb DT, Reed SG.

Front Immunol. 2018 Oct 17;9:2420. doi: 10.3389/fimmu.2018.02420. eCollection 2018.


A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen.

Van Hoeven N, Wiley S, Gage E, Fiore-Gartland A, Granger B, Gray S, Fox C, Clements DE, Parks DE, Winram S, Stinchcomb DT, Reed SG, Coler RN.

NPJ Vaccines. 2018 Sep 26;3:39. doi: 10.1038/s41541-018-0077-1. eCollection 2018.


A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.

Erasmus JH, Khandhar AP, Guderian J, Granger B, Archer J, Archer M, Gage E, Fuerte-Stone J, Larson E, Lin S, Kramer R, Coler RN, Fox CB, Stinchcomb DT, Reed SG, Van Hoeven N.

Mol Ther. 2018 Oct 3;26(10):2507-2522. doi: 10.1016/j.ymthe.2018.07.010. Epub 2018 Aug 2.


Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.

Strouts FR, Popper SJ, Partidos CD, Stinchcomb DT, Osorio JE, Relman DA.

PLoS Negl Trop Dis. 2016 May 23;10(5):e0004731. doi: 10.1371/journal.pntd.0004731. eCollection 2016 May.


Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.

Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, Sariol CA, Shek LP, Simasathien S, Smith MK, Velez ID, Wallace D, Gordon GS, Stinchcomb DT.

J Infect Dis. 2016 May 15;213(10):1562-72. doi: 10.1093/infdis/jiv762. Epub 2015 Dec 23.


A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.

Osorio JE, Wallace D, Stinchcomb DT.

Expert Rev Vaccines. 2016;15(4):497-508. doi: 10.1586/14760584.2016.1128328. Epub 2016 Feb 22. Review.


Development of a recombinant, chimeric tetravalent dengue vaccine candidate.

Osorio JE, Partidos CD, Wallace D, Stinchcomb DT.

Vaccine. 2015 Dec 10;33(50):7112-20. doi: 10.1016/j.vaccine.2015.11.022. Epub 2015 Nov 14. Review.


Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.

Rupp R, Luckasen GJ, Kirstein JL, Osorio JE, Santangelo JD, Raanan M, Smith MK, Wallace D, Gordon GS, Stinchcomb DT.

Vaccine. 2015 Nov 17;33(46):6351-9. doi: 10.1016/j.vaccine.2015.09.008. Epub 2015 Sep 15.


CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.

Chu H, George SL, Stinchcomb DT, Osorio JE, Partidos CD.

J Infect Dis. 2015 Nov 15;212(10):1618-28. doi: 10.1093/infdis/jiv258. Epub 2015 May 5.


Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.

George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE, Haller AA, Osorio JE, Eggemeyer LM, Irby-Moore S, Frey SE, Huang CY, Stinchcomb DT.

J Infect Dis. 2015 Oct 1;212(7):1032-41. doi: 10.1093/infdis/jiv179. Epub 2015 Mar 19.


Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.

Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC.

J Virol. 2014 Nov;88(22):13418-28. doi: 10.1128/JVI.01219-14. Epub 2014 Sep 10.


Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.

Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA, Silengo S, Scott J, Boroughs KL, Stovall JL, Luy BE, Arguello J, Beatty ME, Santangelo J, Gordon GS, Huang CY, Stinchcomb DT.

Lancet Infect Dis. 2014 Sep;14(9):830-8. doi: 10.1016/S1473-3099(14)70811-4. Epub 2014 Jul 23.


A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates.

Ambuel Y, Young G, Brewoo JN, Paykel J, Weisgrau KL, Rakasz EG, Haller AA, Royals M, Huang CY, Capuano S, Stinchcomb DT, Partidos CD, Osorio JE.

Front Immunol. 2014 Jun 5;5:263. doi: 10.3389/fimmu.2014.00263. eCollection 2014. Erratum in: Front Immunol. 2014;5:436.


Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).

Huang CY, Kinney RM, Livengood JA, Bolling B, Arguello JJ, Luy BE, Silengo SJ, Boroughs KL, Stovall JL, Kalanidhi AP, Brault AC, Osorio JE, Stinchcomb DT.

PLoS Negl Trop Dis. 2013 May 30;7(5):e2243. doi: 10.1371/journal.pntd.0002243. Print 2013.


Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.

Chu H, Das SC, Fuchs JF, Suresh M, Weaver SC, Stinchcomb DT, Partidos CD, Osorio JE.

Vaccine. 2013 Jul 18;31(33):3353-60. doi: 10.1016/j.vaccine.2013.05.059. Epub 2013 May 29.


Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.

Brewoo JN, Powell TD, Jones JC, Gundlach NA, Young GR, Chu H, Das SC, Partidos CD, Stinchcomb DT, Osorio JE.

Vaccine. 2013 Apr 3;31(14):1848-55. doi: 10.1016/j.vaccine.2013.01.038. Epub 2013 Feb 1.


Chikungunya virus and prospects for a vaccine.

Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT.

Expert Rev Vaccines. 2012 Sep;11(9):1087-101. doi: 10.1586/erv.12.84. Review.


Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.

Partidos CD, Paykel J, Weger J, Borland EM, Powers AM, Seymour R, Weaver SC, Stinchcomb DT, Osorio JE.

Vaccine. 2012 Jun 29;30(31):4638-43. doi: 10.1016/j.vaccine.2012.04.099. Epub 2012 May 11.


Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice.

Brewoo JN, Kinney RM, Powell TD, Arguello JJ, Silengo SJ, Partidos CD, Huang CY, Stinchcomb DT, Osorio JE.

Vaccine. 2012 Feb 14;30(8):1513-20. doi: 10.1016/j.vaccine.2011.11.072. Epub 2011 Dec 13.


Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism.

Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, Borland EM, Powers AM, Seymour R, Stinchcomb DT, Osorio JE, Frolov I, Weaver SC.

PLoS Pathog. 2011 Jul;7(7):e1002142. doi: 10.1371/journal.ppat.1002142. Epub 2011 Jul 28.


Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines.

Wiggan O, Livengood JA, Silengo SJ, Kinney RM, Osorio JE, Huang CY, Stinchcomb DT.

Vaccine. 2011 Oct 6;29(43):7456-62. doi: 10.1016/j.vaccine.2011.07.054. Epub 2011 Jul 29.


Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

Osorio JE, Huang CY, Kinney RM, Stinchcomb DT.

Vaccine. 2011 Sep 23;29(42):7251-60. doi: 10.1016/j.vaccine.2011.07.020. Epub 2011 Jul 21. Review.


Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

Osorio JE, Brewoo JN, Silengo SJ, Arguello J, Moldovan IR, Tary-Lehmann M, Powell TD, Livengood JA, Kinney RM, Huang CY, Stinchcomb DT.

Am J Trop Med Hyg. 2011 Jun;84(6):978-87. doi: 10.4269/ajtmh.2011.10-0592.


Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling.

Partidos CD, Weger J, Brewoo J, Seymour R, Borland EM, Ledermann JP, Powers AM, Weaver SC, Stinchcomb DT, Osorio JE.

Vaccine. 2011 Apr 5;29(16):3067-73. doi: 10.1016/j.vaccine.2011.01.076. Epub 2011 Feb 5.


Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.

Brewoo JN, Powell TD, Stinchcomb DT, Osorio JE.

Vaccine. 2010 Aug 16;28(36):5891-9. doi: 10.1016/j.vaccine.2010.06.054. Epub 2010 Jul 12.


Immunization of black-tailed prairie dog against plague through consumption of vaccine-laden baits.

Rocke TE, Smith SR, Stinchcomb DT, Osorio JE.

J Wildl Dis. 2008 Oct;44(4):930-7.


Identification of serum biomarkers for canine B-cell lymphoma by use of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry.

Gaines PJ, Powell TD, Walmsley SJ, Estredge KL, Wisnewski N, Stinchcomb DT, Withrow SJ, Lana SE.

Am J Vet Res. 2007 Apr;68(4):405-10.


Limited infection upon human exposure to a recombinant raccoon pox vaccine vector.

Rocke TE, Dein FJ, Fuchsberger M, Fox BC, Stinchcomb DT, Osorio JE.

Vaccine. 2004 Jul 29;22(21-22):2757-60.


Raccoon poxvirus as a mucosal vaccine vector for domestic cats.

Osorio JE, Frank RS, Moss K, Taraska T, Powell T, Stinchcomb DT.

J Drug Target. 2003;11(8-10):463-70.


Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors.

Thamm DH, Kurzman ID, Macewen EG, Feinmehl R, Towell TL, Longhofer SL, Johnson CM, Geoly FJ, Stinchcomb DT.

Cancer Immunol Immunother. 2003 Aug;52(8):473-80. Epub 2003 May 27.


Recombinant raccoon pox vaccine protects mice against lethal plague.

Osorio JE, Powell TD, Frank RS, Moss K, Haanes EJ, Smith SR, Rocke TE, Stinchcomb DT.

Vaccine. 2003 Mar 7;21(11-12):1232-8.


Immunization of dogs and cats with a DNA vaccine against rabies virus.

Osorio JE, Tomlinson CC, Frank RS, Haanes EJ, Rushlow K, Haynes JR, Stinchcomb DT.

Vaccine. 1999 Mar 5;17(9-10):1109-16.


Anti-gene therapy: the use of ribozymes to inhibit gene function.

Couture LA, Stinchcomb DT.

Trends Genet. 1996 Dec;12(12):510-5. Review.


Optimizing the cell efficacy of synthetic ribozymes. Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb.

Jarvis TC, Wincott FE, Alby LJ, McSwiggen JA, Beigelman L, Gustofson J, DiRenzo A, Levy K, Arthur M, Matulic-Adamic J, Karpeisky A, Gonzalez C, Woolf TM, Usman N, Stinchcomb DT.

J Biol Chem. 1996 Nov 15;271(46):29107-12.


PAR-2 is asymmetrically distributed and promotes association of P granules and PAR-1 with the cortex in C. elegans embryos.

Boyd L, Guo S, Levitan D, Stinchcomb DT, Kemphues KJ.

Development. 1996 Oct;122(10):3075-84.


Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA.

Jarvis TC, Alby LJ, Beaudry AA, Wincott FE, Beigelman L, McSwiggen JA, Usman N, Stinchcomb DT.

RNA. 1996 May;2(5):419-28.


Constraining the cell cycle: regulating cell division and differentiation by gene therapy.

Stinchcomb DT.

Nat Med. 1995 Oct;1(10):1004-6. No abstract available.


Toward the therapeutic editing of mutated RNA sequences.

Woolf TM, Chase JM, Stinchcomb DT.

Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8298-302.


Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter.

Thompson JD, Ayers DF, Malmstrom TA, McKenzie TL, Ganousis L, Chowrira BM, Couture L, Stinchcomb DT.

Nucleic Acids Res. 1995 Jun 25;23(12):2259-68.


Ribozymes in gene therapy.

Thompson JD, Macejak D, Couture L, Stinchcomb DT.

Nat Med. 1995 Mar;1(3):277-8. Review. No abstract available.


par-2, a gene required for blastomere asymmetry in Caenorhabditis elegans, encodes zinc-finger and ATP-binding motifs.

Levitan DJ, Boyd L, Mello CC, Kemphues KJ, Stinchcomb DT.

Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6108-12.


Characterization of cytokine production by the metrial gland and granulated metrial gland cells.

Croy BA, Guilbert LJ, Browne MA, Gough NM, Stinchcomb DT, Reed N, Wegmann TG.

J Reprod Immunol. 1991 Feb;19(2):149-66.


Extrachromosomal DNA transformation of Caenorhabditis elegans.

Stinchcomb DT, Shaw JE, Carr SH, Hirsh D.

Mol Cell Biol. 1985 Dec;5(12):3484-96.


Caenorhabditis elegans DNA that directs segregation in yeast cells.

Stinchcomb DT, Mello C, Hirsh D.

Proc Natl Acad Sci U S A. 1985 Jun;82(12):4167-71.


Genes affecting early development in Caenorhabditis elegans.

Hirsh D, Kemphues KJ, Stinchcomb DT, Jefferson R.

Cold Spring Harb Symp Quant Biol. 1985;50:69-78. No abstract available.


Centromeric DNA from Saccharomyces cerevisiae.

Stinchcomb DT, Mann C, Davis RW.

J Mol Biol. 1982 Jun 25;158(2):157-90. No abstract available.


Studies on the transposable element Ty1 of yeast. I. RNA homologous to Ty1. II. Recombination and expression of Ty1 and adjacent sequences.

Elder RT, St John TP, Stinchcomb DT, Davis RW, Scherer S, Davis RW.

Cold Spring Harb Symp Quant Biol. 1981;45 Pt 2:581-91. No abstract available.


Eukaryotic DNA segments capable of autonomous replication in yeast.

Stinchcomb DT, Thomas M, Kelly J, Selker E, Davis RW.

Proc Natl Acad Sci U S A. 1980 Aug;77(8):4559-63.

Supplemental Content

Loading ...
Support Center